Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53

Urology

Volumn 47, Issue 3, 1996, Pages 366-369

  Stricker, Hans J ^a   Jay, Jonathan K ^a   Linden, Michael D ^a   Tamboli, Pheroze ^a   Amin, Mahul B ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SEMINAL VESICLE DISEASE; TUMOR SUPPRESSOR GENE;

EID: 0029922216     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80454-3     Document Type: Article

References (19)

1. Tannenbaum M, Tannenbaum S, deSanctis PN, and Olsson CA: Prognostic significance of nucleolar surface area in prostate cancer. Urology 19: 546-551, 1982.
2. Lundberg S, Carstensen J, and Rundquist I: DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in survival study. Cancer Res 47: 1973-1977, 1987.
3. Jones EC, McNeal J, Bruchovsky N, and deJong G: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 66: 752-757, 1990.
4. Batsakis JG, and El-Naggar AK: p53: fifteen years after discovery. Adv Anat Pathol 2: 71-88, 1995.
5. Soussi T, Legros Y, Lubin R, Ory K, and Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1-9, 1994.
6. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, Birnbaum D, and Theillet C: p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69: 846-852, 1994.
7. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, and Conti AJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993.
8. Levine AJ, Momand J, and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
9. Hollstein M, Sidransky D, Vogelstein B, and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
10. Gown AM, de Wever N, and Battifora H: Microwave-based antigenic unmasking; a revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 114: 256-266, 1993.
11. Resnick JM, Cherwitz D, Knapp D, Uhlman D, and Niehans GA: A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 119: 360-366, 1995.
12. Linden MD, Nathanson SD, and Zarbo RJ: Evaluation of anti-p53 antibody staining quality control and technical considerations. Appl Immunohistochem 2: 218-224, 1994.
13. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, and Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
14. Soini Y, Paakko P, Nuorva K, Kamel D, Lane DP, and Vahakangas K: Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A Pathol Anat Histopathol 421: 223-228, 1992.
15. Grignon DJ, Chen YQ, Sarkar FH, Sakr WA, Gao X, Borders J, Honn KV, and Crissman JD: p53 abnormalities in prostatic adenocarcinoma. Mod Pathol 7: 75A, 1994.
16. Lee SS, Ro JY, Kwon DH, Jin SW, Yoo WD, Park SN, and Ayala AG: Detection of human papillomavirus (HPV) DNA, p53 expression and proliferating cell nuclear antigen (PCNA) activity in prostatic carcinoma. Mod Pathol 8: 79A, 1995.
17. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, and Srivastava S: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154: 414-421, 1995.
18. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, and Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993.
19. Dillioglugil O, Leibman BD, Kattan M, Seale-Hawkins C, and Scardino PT: Hazard rates for progression, determined by PSA, after radical prostatectomy for T1-2 prostate cancer. J Urol 153: 391A, 1995.